丹参酮I|T2907|TargetMol

Tanshinone I
568-73-0

￥327 5mg 起订

￥472 10mg 起订

￥793 25mg 起订

上海更新日期：2024-09-24

TargetMol中国（陶术生物）

VIP12年

联系人：邵小姐

电话：021-021-33632979拨打

手机：15002134094 拨打

邮箱：marketing@targetmol.com

产品详情:

中文名称：: 丹参酮I

英文名称：: Tanshinone I

CAS号：: 568-73-0

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 98.58%

产品类别：: 抑制剂

货号：: T2907

Product Introduction

Bioactivity

名称	Tanshinone I
描述	Tanshinone I (Tanshinone A), an active principle isolated from the herbal medicine Salvia miltiorrhiza, displays cytotoxicity against tumor cells.
细胞实验	RAW 264.7 cells are cultured with DMEM supplemented with 10% FBS and 1% antibiotics under 5% CO2 at 37°C. Briefly, cells are plated in 96-well plates (2×105 cells/well). LPS (1 ug/mL) and Tanshinone I are simultaneously added and incubated for 24 h, unless otherwise specified. The PGE2 concentration in the medium is measured using an EIA kit for PGE2. In order to determine the effects of Tanshinone I on PGE2 production after induction of COX-2, cells are incubated with LPS (1 ug/mL) for 24 h and thoroughly washed. Then, Tanshinone I is added without LPS and the cells are incubated for another 24 h. From the medium, PGE2 concentrations are measured. The cytotoxicity of Tanshinone I to RAW cells is checked using the MTT assay. Tanshinone I does not show any cytotoxicity up to 100 uM[1].
激酶实验	As sources of PLA2, human recombinant sPLA2 (type IIA) is purified from CHO cells transfected with the PLA2 gene and rabbit recombinant platelet cPLA2 is obtained through its expression in baculovirus. The standard reaction mixture (200 μL) contained 100 mM Tris-HCl buffer (pH 9.0) with 6 mM CaCl2 and 20 nmol 1-acyl-[1-14C]-arachidonyl-sn-glycerophosphoethanolamine (2000 cpm/nmol) in the presence or absence of Tanshinone I. The reaction is started by adding 50 ng purified sPLA2 or cPLA2. After 20 min at 37°C, the free fatty acid generated is analysed. Under these standard conditions, the reaction mixture in the absence of Tanshinone I released approximately 10% of free fatty acid from the phospholipid substrate added[1].
体内活性	Tanshinone I在大鼠肉胶原（CGN）诱导的爪肿胀和大鼠佐剂诱导性关节炎（AIA）模型中展示了抗炎活性，这些模型是研究急性和慢性炎症的经典动物模型。口服Tanshinone I对CGN诱导的爪肿胀表现出显著的抗炎活性（160 mg/kg时，抑制率为47%），而indomethacin的IC50为7.1 mg/kg。在AIA模型中，Tanshinone I以每日口服50 mg/kg的剂量，在第18天抑制二次炎炎症27%，而prednisolone（每日5 mg/kg）展现出更强的抑制效果（65%）[1]。
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 2.5 mg/mL (9.05 mM), Sonication is recommended.
关键字	inhibit \| Phospholipase \| Inhibitor \| Tanshinone I
相关产品	Fluticasone (propionate) \| 1-Naphthaleneacetic acid \| Amentoflavone \| Indomethacin \| 1-Naphthaleneacetic acid potassium salt \| Lansoprazole \| Tris(2,4-di-tert-butylphenyl)phosphate \| Benzylideneacetone \| (E/Z)-Polydatin \| Neomycin sulfate \| Darapladib \| trans-Benzylideneacetone
相关库	经典已知活性库 \| 抗癌活性化合物库 \| 已知活性化合物库 \| 中药抗炎分子库 \| 药物功能重定位化合物库 \| 高通量筛选天然产物库 \| 抗癌药物库

Tanshinone A|||丹参酮I|TargetMol

上海陶术生物科技有限公司为美国Target Molecule Corp. ( Target Mol ) 在上海建立的全资子公司。我们与美国波士顿、德国慕尼黑的同事一起，为北美、欧洲和亚洲从事药物研发和生物学研究的科学家提供优质的产品和专业的服务。公司下设筛选事业部，化学事业部，生物事业部和新材料部。从虚拟筛选到实体化合物分子供应；从商业化产品销售到个性化定制合成；从对明确靶点的分子筛选到对明确分子的多靶点筛选，从高通量筛选到化学结构优化，我们都可以满足您的科研用品及技术服务的需求。经过在中国市场五年的精心耕耘，我们已成为筛选化合物领域优秀的供应商，为超过五百家学校和各类企业提供了品质卓越的小分子化合物和药物筛

成立日期	(12年)
注册资本	566.2651万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,试剂,定制,服务
主营行业	化学试剂,生物活性小分子